Your browser is no longer supported. Please, upgrade your browser.
ACIU [NASD]
AC Immune SA
Index- P/E- EPS (ttm)-1.09 Insider Own51.38% Shs Outstand72.31M Perf Week-5.43%
Market Cap435.54M Forward P/E- EPS next Y-0.09 Insider Trans0.00% Shs Float34.46M Perf Month-11.21%
Income-78.20M PEG- EPS next Q-0.27 Inst Own29.10% Short Float3.79% Perf Quarter-20.26%
Sales3.70M P/S117.71 EPS this Y-234.80% Inst Trans2.85% Short Ratio1.54 Perf Half Y10.91%
Book/sh3.16 P/B1.93 EPS next Y87.10% ROA-28.50% Target Price- Perf Year-21.19%
Cash/sh3.34 P/C1.83 EPS next 5Y- ROE-31.30% 52W Range4.42 - 13.00 Perf YTD17.99%
Dividend- P/FCF- EPS past 5Y-33.80% ROI-28.10% 52W High-53.08% Beta0.75
Dividend %- Quick Ratio19.80 Sales past 5Y-17.00% Gross Margin- 52W Low38.01% ATR0.37
Employees149 Current Ratio19.80 Sales Q/Q- Oper. Margin- RSI (14)35.64 Volatility5.75% 5.51%
OptionableYes Debt/Eq0.01 EPS Q/Q-116.30% Profit Margin- Rel Volume0.21 Prev Close6.15
ShortableYes LT Debt/Eq0.01 EarningsMar 23 BMO Payout- Avg Volume849.97K Price6.10
Recom1.70 SMA20-8.52% SMA50-15.58% SMA200-5.33% Volume179,092 Change-0.81%
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Apr-28-21 08:45AM  
07:00AM  
Apr-20-21 12:00PM  
Mar-31-21 07:00AM  
Mar-28-21 03:00AM  
Mar-26-21 07:00AM  
Mar-25-21 01:28AM  
Mar-23-21 08:01AM  
07:00AM  
Mar-16-21 07:00AM  
Mar-09-21 07:00AM  
Feb-24-21 07:00AM  
Feb-17-21 07:00AM  
Feb-11-21 08:24PM  
04:23PM  
08:16AM  
07:00AM  
Feb-08-21 07:00AM  
Jan-29-21 07:00AM  
Jan-24-21 01:01AM  
Jan-17-21 11:13PM  
Dec-15-20 08:00AM  
Dec-11-20 12:54PM  
Nov-20-20 08:40AM  
Nov-18-20 07:00AM  
Nov-13-20 10:10AM  
07:27AM  
07:00AM  
Nov-12-20 07:00AM  
Nov-09-20 04:00AM  
Nov-04-20 12:30PM  
Oct-09-20 08:25AM  
Oct-05-20 06:39AM  
Sep-24-20 10:35AM  
Sep-23-20 10:19AM  
07:00AM  
Sep-11-20 07:00AM  
Sep-01-20 08:54AM  
Aug-21-20 08:05AM  
Aug-07-20 10:53AM  
Aug-06-20 12:00PM  
Aug-05-20 11:25AM  
07:00AM  
Aug-03-20 07:00AM  
Jul-30-20 07:55AM  
Jul-28-20 07:00AM  
Jul-23-20 07:00AM  
Jul-17-20 10:04AM  
07:41AM  
Jul-16-20 04:25PM  
03:01PM  
08:29AM  
07:00AM  
Jul-07-20 09:00AM  
06:51AM  
Jul-04-20 02:59PM  
Jun-26-20 07:21AM  
May-15-20 07:00AM  
May-06-20 10:12AM  
May-04-20 08:35AM  
07:00AM  
Apr-28-20 11:16AM  
Apr-04-20 08:04AM  
Apr-02-20 07:00AM  
Mar-30-20 07:00AM  
Mar-24-20 10:31AM  
Mar-23-20 07:00AM  
Mar-20-20 07:19AM  
Mar-18-20 09:43AM  
Mar-13-20 09:22AM  
Mar-05-20 07:00AM  
Feb-24-20 07:23AM  
Jan-30-20 10:37AM  
Dec-24-19 04:57AM  
Dec-16-19 01:46PM  
Nov-14-19 07:00AM  
Nov-13-19 07:00AM  
Nov-11-19 07:50AM  
Nov-08-19 10:25AM  
Nov-06-19 04:05PM  
02:31PM  
Nov-05-19 10:33AM  
Oct-24-19 07:00AM  
Sep-25-19 08:52AM  
Sep-23-19 01:22PM  
Sep-20-19 10:02AM  
07:00AM  
Sep-17-19 02:00AM  
Sep-04-19 07:00AM  
Aug-19-19 12:31PM  
Aug-14-19 07:00AM  
Aug-12-19 07:00AM  
Aug-07-19 10:30AM  
Jul-18-19 10:26AM  
Jul-17-19 07:00AM  
Jul-11-19 08:00AM  
Jul-10-19 10:52AM  
Jun-29-19 06:07PM  
Jun-28-19 08:36AM  
Jun-27-19 07:00AM  
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.